FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray

FDA has become aware of safety reports involving compounded intranasal ketamine to treat psychiatric disorders which may be putting patients at risk. Compounded drugs are not FDA-approved, which means FDA has not evaluated their safety, effectiveness, or quality prior to marketing.

https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-professionals-potential-risks-associated-compounded-ketamine-nasal-spray

Popular posts from this blog

The Concept of Treatment-Refractory Addiction: A Call to the Field

EXPANDING MAIL-BASED DISTRIBUTION OF DRUG-RELATED HARM REDUCTION SUPPLIES AMID COVID-19 AND BEYOND